Education
About Us
Working with TipRanks
Follow Us
Ipsen (FR:IPN)
:IPN
IPN Stock Chart & Stats
€157.30
€0.40(0.34%)
At close: 4:00 PM EST
€157.30
€0.40(0.34%)
Day’s Range― - ―
52-Week Range€87.95 - €158.20
Previous CloseN/A
Volume2.80K
Average Volume (3M)64.26K
Market Cap
€12.87B
Enterprise Value€12.57B
Total Cash (Recent Filing)€1.45B
Total Debt (Recent Filing)€961.80M
Price to Earnings (P/E)29.2
Beta0.53
Next Earnings
Jul 23, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield1.17%
Share Statistics
EPS (TTM)6.02
Shares Outstanding83,814,530
10 Day Avg. Volume52,964
30 Day Avg. Volume64,259
Financial Highlights & Ratios
PEG Ratio-0.57
Price to Book (P/B)2.19
Price to Sales (P/S)2.56
P/FCF Ratio68.89
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€133.00Price Target Upside-15.45% Downside
Rating ConsensusHold
Number of Analyst Covering3
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue Growth & Therapeutic PortfolioSustained ~9.6% revenue growth and a diversified specialty portfolio (oncology, neurology, rare diseases) indicate durable demand for core therapies. This supports predictable top-line expansion and reduces reliance on any single product over the next several quarters.
Balance Sheet StrengthA solid equity base and falling leverage improve financial flexibility for R&D investment, M&A or trials funding. Lower leverage reduces liquidity risk and supports long-term resilience through clinical cycles and regulatory timelines common in biotech.
Operating Cash GenerationConsistent operating cash generation relative to earnings underpins internal funding of development programs and operations. Strong OCF sustains capital expenditure and clinical investment without excessive external financing over a multi-quarter horizon.
Bears Say
Declining Net Profit MarginA falling net margin points to rising costs or pricing pressure that can erode long-term free cash conversion. If persistent, margin compression may constrain reinvestment, limit shareholder returns, and require structural cost or portfolio actions to restore profitability.
Drop In Free Cash FlowA marked decline in free cash flow reduces the company's ability to self-fund R&D, milestone payments, or opportunistic acquisitions. Sustained FCF weakness would increase reliance on external capital, raising execution risk for multi-year development programs.
Earnings Volatility (EPS Decline)A sharp year-over-year EPS decline signals earnings volatility that can reflect product or margin pressures. Persistent EPS weakness undermines internal funding capacity and could constrain strategic flexibility, affecting long-term R&D pacing and shareholder returns.
Ipsen News
IPN FAQ
What was Ipsen’s price range in the past 12 months?
Ipsen lowest stock price was €87.95 and its highest was €158.20 in the past 12 months.
What is Ipsen’s market cap?
Ipsen’s market cap is €12.87B.
When is Ipsen’s upcoming earnings report date?
Ipsen’s upcoming earnings report date is Jul 23, 2026 which is in 153 days.
How were Ipsen’s earnings last quarter?
Ipsen released its earnings results on Feb 12, 2026. The company reported €6.02 earnings per share for the quarter, beating the consensus estimate of €5.527 by €0.493.
Is Ipsen overvalued?
According to Wall Street analysts Ipsen’s price is currently Overvalued.
Does Ipsen pay dividends?
Ipsen pays a Annually dividend of €1.4 which represents an annual dividend yield of 1.17%. See more information on Ipsen dividends here
What is Ipsen’s EPS estimate?
Ipsen’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Ipsen have?
Ipsen has 83,814,530 shares outstanding.
What happened to Ipsen’s price movement after its last earnings report?
Ipsen reported an EPS of €6.02 in its last earnings report, beating expectations of €5.527. Following the earnings report the stock price went up 6.34%.
Which hedge fund is a major shareholder of Ipsen?
Currently, no hedge funds are holding shares in FR:IPN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Ipsen
Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, gastroenterology, cognitive disorders, and rare diseases. It offers Somatuline for neuroendocrine tumors and acromegaly; Decapeptyl for the treatment of advanced metastatic prostate cancer; Cabometyx for renal cell and second-line hepatocellular carcinoma; Onivyde for second-line metastatic pancreatic cancer; Dysport for motor muscular disorders and medical aesthetics; NutropinAq for growth failure in children due to growth hormone (GH) deficiency, turner syndrome, chronic renal failure, and GH deficiency in adults; and Increlex for growth failure in children and adolescents. The company also offers Smecta for chronic and acute diarrhea, and pain associated with functional bowel diseases; Forlax for constipation; Fortrans/Eziclen for bowel cleansing prior to endoscopy, X-ray examination, and colonic surgery; and Tanakan for cognitive disorders in adults, vertigo of vestibular origin and vestibular rehabilitation, and tinnitus. In addition, it provides Xermelo for the carcinoid syndrome; Cometriq for medullary thyroid cancer; Smebiocta/SmectaFlora Protect, a food supplement; SmectaGas, a medical device used in the symptomatic treatment of gas-related gastrointestinal disorders and relief of gas-related symptoms; and Etiasa for inflammatory bowel diseases. Further, the company offers other consumer healthcare products in the gastro-intestinal area, including Buscopan, Clin4000, Prontalgine, Suppositoria Glycerini, Mucothiol, Floractin, and Mucodyne. Ipsen S.A. has agreements with Debiopharm; Exelixis; Galderma; Blueprint Medicines; TerSera Therapeutics; Rhythm Pharmaceuticals; Teijin; Braintree Laboratories; Ethypharm; Schwabe; BAKX Therapeutics Inc.; and Exicure. The company was founded in 1929 and is headquartered in Boulogne-Billancourt, France.
IPN Stock 12 Month Forecast
Average Price Target
€133.00
▼(-15.45% Downside)
Technical Analysis
Options Prices
Currently, No data available
---